ASRS 2025: A look at the phase 3 ARCHER II trial of vonaprument for dry AMD with geographic atrophy
David Eichenbaum, MD, recently gave a presentation at the American Society of Retina Specialists (ASRS) Annual Meeting about enrollment for the phase 3 ARCHER II trial of vonaprument for dry age-related macular degeneration with geographic atrophy (GA).
David Eichenbaum, MD:
I’m David Eichenbaum, director of research at Retina Vitreous Associates of Florida. I’m very excited to be presenting at the American Society of Retina Specialists in Long Beach, California, Annexon’s information on their phase 3 clinical trial, ARCHER II. This is the design of the study and this is informed by the results of the phase 2 ARCHER clinical trial. There are 4 takeaways from my presentation.
Number 1, the clinical trial phase 3 ARCHER II is fully enrolled. We just completed enrollment immediately prior to the meeting and it’s very exciting.
Number 2, vonaprument, which is the name of ANX007, is being tested in a fashion informed by the phase 2 clinical trial. Patients with center-involved disease and non-center-involved disease are all being enrolled. Patients need to have vision of 45 ETDRS letters or more, so they are 20/100 or better. This is the only clinical trial for GA looking at registration with an endpoint that has approvable worldwide. This is because the EMA requires a visual functional endpoint, and the endpoint analysis for ARCHER II is an event analysis looking at preservation of vision. This pathway means vonaprument may be the only GA therapy with worldwide registration following the readout of this phase 3 trial.
It’s truly a privilege to be here, and I’m excited to talk about the full enrollment of ARCHER II.
Related Content
